1 paper and 0 clinical trials exploring ayahuasca as a treatment for health economics & reimbursement.
Ayahuasca is a botanical decoction combining DMT with MAO-inhibiting harmala alkaloids, producing intense psychedelic effects lasting 3-6 hours. Clinical trials show rapid, large antidepressant effects from a single dose, with a favourable safety profile in controlled settings.
Full Ayahuasca profilePsychedelic-assisted therapies are gaining traction in the health economics domain, with promising findings regarding their efficacy in treating mental health disorders. As the FDA considers approval for compounds like MDMA and psilocybin, the economic implications, including reimbursement models, are increasingly relevant to healthcare systems worldwide.
Full Health Economics & Reimbursement profileNo clinical trials have been tagged with both Ayahuasca and Health Economics & Reimbursement yet.
Trials are continuously being added as new studies are registered.